GFAP and central nervous system cancer: Although previous researchers have demonstrated that GFAP in patients with higher-grade gliomas was more expressed than those with lower-grade gliomas [18], we found a different result that the protein level of GFAP was unrelated with the possibility of CDC42EP3 overexpression with the latter positively correlating with tumor pathological grading.